Roche Investor UpdateThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest items in this publication.

Pages: 1 2 3 4

160 records returned

ACTEMRA Improves Signs and Symptoms in Children with Systemic Onset Juvenile Idiopathic Arthritis (sJIA)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche announced today that ACTEMRA (tocilizumab, known as RoACTEMRA within the EU) successfully met its primary endpoint in a paediatric study of systemic onset Juvenile Idiopathic Arthritis (sJIA), by significantly improving disease signs and symptoms, a critical effectiveness measure of a sJIA treatment. (Source: Roche Investor Update)
Source: Roche Investor Update - November 20, 2009 Category: Pharmaceuticals Source Type: organizations

US FDA issues complete response letter for Rituxan/MabThera for chronic lymphocytic leukaemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche announced today that the US Food and Drug Administration (FDA) issued a complete response to Genentech, a wholly-owned member of the Roche Group, and Biogen Idec (Nasdaq: BIIB) on the companies’ applications for Rituxan/MabThera (rituximab) plus fludarabine and cyclophosphamide (FC) chemotherapy for the treatment of for the treatment of patients with previously untreated and previously treated chronic lymphocytic leukaemia (CLL). (Source: Roche Investor Update)
Source: Roche Investor Update - November 18, 2009 Category: Pharmaceuticals Source Type: organizations

Invitation to Roche investor science event from SABCS 2009Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We kindly invite investors and analysts to participate in a conference call to discuss new clinical data and results presented during the 32nd Annual San Antonio Breast Cancer Symposium, 9-13 December 2009, San Antonio, Texas. (Source: Roche Investor Update)
Source: Roche Investor Update - November 18, 2009 Category: Pharmaceuticals Source Type: organizations

Roche announces start of new atherosclerosis study (dal-PLAQUE 2) for dalcetrapibEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche today presented new preclinical data further supporting the differentiation of its novel cholesteryl ester transfer protein inhibitor (CETPi) dalcetrapib at this year's Scientific Sessions of the American Heart Association taking place from 14-18 November in Orlando. Based on the current safety and efficacy profile of dalcetrapib, Roche announced a new Phase III clinical trial, dal-PLAQUE 2. (Source: Roche Investor Update)
Source: Roche Investor Update - November 18, 2009 Category: Pharmaceuticals Source Type: organizations

Applications to allow Avastin to be combined with commonly used chemotherapies in advanced breast cancer submitted to FDAEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche announced today that Genentech, a wholly-owned member of the Roche Group, has submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the phase III AVADO study that investigated Avastin in combination with docetaxel chemotherapy. The other is based on the phase III RIBBON-1 study that investigated Avastin in combination with a taxane or anthracycline-based chemotherapy or...
Source: Roche Investor Update - November 17, 2009 Category: Pharmaceuticals Source Type: organizations

FDA Grants Emergency Use Authorization to Roche's Assay for 2009 H1N1 Influenza VirusEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche announced today that it's RealTime ready Influenza A/H1N1 Detection Set for the 2009 H1N1 influenza virus has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA). The Roche kit detects RNA from the 2009 H1N1 influenza A virus and allows rapid and accurate identification of patients infected with this virus. It is important to differentiate patients infected with 2009 H1N1 virus from others with similar symptoms so that appropriate patient management can be commenced as early as possible. The efficacy of the Roche assay was demonstrated by clinical evaluation at worldwide s...
Source: Roche Investor Update - November 16, 2009 Category: Pharmaceuticals Source Type: organizations

Roche reports positive Phase II results with potential first-in-class treatment for the negative symptoms of schizophreniaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche today reports results from a 320 patient phase II proof-of-concept study with it’s investigational glycine transporter-1 inhibitor RG1678. The study showed that the compound improved both the negative symptoms and the personal and social functioning of patients with schizophrenia reaching statistical significance on primary and secondary endpoints. (Source: Roche Investor Update)
Source: Roche Investor Update - November 10, 2009 Category: Pharmaceuticals Source Type: organizations

Invitation to Roche investor science event from ASH 2009 - Conference call on 8 December 2009Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Roche Investor Update)
Source: Roche Investor Update - November 9, 2009 Category: Pharmaceuticals Source Type: organizations

Anti-Malignancy Agent Avastin Obtained Approval for Additional Indication of Non-Small Cell Lung CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Please find attached a press release issued by Chugai in Japan (Source: Roche Investor Update)
Source: Roche Investor Update - November 9, 2009 Category: Pharmaceuticals Source Type: organizations

First Phase III clinical trial of Roche`s weekly taspoglutide meets primary end-point of change in HbA1cEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche today announced that headline results from its Phase III study, T-emerge 2 (subcutaneous weekly taspoglutide versus subcutaneous twice-daily exenatide, as add-on to metformin, a thiazolidinedione [TZD], or metformin and a TZD), showed that the trial met its primary endpoint of change in HbA1c. Superiority versus exenatide was demonstrated. (Source: Roche Investor Update)
Source: Roche Investor Update - October 29, 2009 Category: Pharmaceuticals Source Type: organizations

First Phase III clinical trial of Roche's weekly taspoglutide meets primary end-point of change in HbA1cEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche today announced that headline results from its Phase III study, T-emerge 2 (subcutaneous weekly taspoglutide versus subcutaneous twice-daily exenatide, as add-on to metformin, a thiazolidinedione [TZD], or metformin and a TZD), showed that the trial met its primary endpoint of change in HbA1c. Superiority versus exenatide was demonstrated. (Source: Roche Investor Update)
Source: Roche Investor Update - October 29, 2009 Category: Pharmaceuticals Source Type: organizations

Phase III trial underway to investigate infusion-free administration of Herceptin for women with HER2-positive breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche and Halozyme Therapeutics announced today that a new subcutaneous formulation of Herceptin using Halozyme’s Enhanze technology has entered phase III of its development. This innovative technology could allow patients with HER2-positive breast cancer to administer Herceptin for themselves with or without the support of a healthcare professional once every three weeks via a simple subcutaneous injection. Currently Herceptin, which prolongs lives of patients with this aggressive type of breast cancer, is given intravenously typically in a hospital setting at the same frequency. (Source: Roche Investor Update)
Source: Roche Investor Update - October 22, 2009 Category: Pharmaceuticals Source Type: organizations

Genentech and Biogen Idec Receive a Complete Response from FDA for Earlier Use of Rituxan for Rheumatoid ArthritisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Please find attached a press release issued by Genentech and Biogen Idec in the US with respect to the approval of Rituxan in early and late stage rheumatoid arthritis in the US. (Source: Roche Investor Update)
Source: Roche Investor Update - October 19, 2009 Category: Pharmaceuticals Source Type: organizations

Anti-Malignancy Agent/Anti-VEGF Humanized Monoclonal Antibody, Avastin Application for Approval of Additional Indication of Breast CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Please find enclosed a press release by Chugai (Source: Roche Investor Update)
Source: Roche Investor Update - October 16, 2009 Category: Pharmaceuticals Source Type: organizations

Roche reports further accelerated sales growth in third quarterEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Group sales up 3.1 billion to 36.4 billion Swiss francs in first nine months, an increase of 11% in local currencies (9% in Swiss francs); both divisions grow significantly faster than their respective markets; Genentech integration progressing successfully; New Group leadership appointed (Source: Roche Investor Update)
Source: Roche Investor Update - October 15, 2009 Category: Pharmaceuticals Source Type: organizations

Reminder: Roche's Third Quarter Sales 2009 Conference CallEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche will publish its Sales Results for the 3rd Quarter of 2009 prior to the opening of the Swiss Stock Exchange on Thursday 15th October, 2009. (Source: Roche Investor Update)
Source: Roche Investor Update - October 7, 2009 Category: Pharmaceuticals Source Type: organizations

Two Phase III studies of Lucentis show early and sustained improvement in vision in patients with retinal vein occlusionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Genentech, Inc., a wholly-owned member of the Roche Group yesterday announced results from two Phase III studies of Lucentis® (ranibizumab injection) in macular edema due to retinal vein occlusion (RVO), which showed, on average, patients given either of two doses of Lucentis had a clinically and statistically significant improvement in vision as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity (BCVA) at six months compared to patients receiving sham injections. Results from both trials were presented today at the Retina Congress 2009 meeting. (Source: Roche Investor Update)
Source: Roche Investor Update - October 5, 2009 Category: Pharmaceuticals Source Type: organizations

RoACTEMRA filed in Europe for the Inhibition of Joint Damage and Improvement in Physical Function in Rheumatoid ArthritisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche announced today that it has submitted a filing to the European health authorities (the European Medicines Agency) to extend the indication of RoACTEMRA to inhibit the progression of joint damage and to improve physical function in patients with rheumatoid arthritis (RA). Joint damage in RA often begins early in the disease and can lead to permanent disability, so inhibiting this structural damage to patients' joints is a critical measure of effectiveness of an RA treatment. (Source: Roche Investor Update)
Source: Roche Investor Update - September 30, 2009 Category: Pharmaceuticals Source Type: organizations

Roche provides update on early-stage breast cancer study with AvastinEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche has been informed by the National Cancer Institute and US Eastern Cooperative Oncology Group (ECOG) that they have suspended enrollment into a phase III clinical trial (E5103) evaluating Avastin® (bevacizumab) in combination with chemotherapy in women with early-stage breast cancer based on a pre-planned cardio-toxicity analysis of the first 200 patients enrolled. The protocol for the trial specifies that enrollment be suspended if six or more cases of clinical congestive heart failure (CHF) are seen in the first 200 patients. This threshold has been met. (Source: Roche Investor Update)
Source: Roche Investor Update - September 25, 2009 Category: Pharmaceuticals Source Type: organizations

Herceptin provides impressive survival benefit for patients with high levels of HER2 in their stomach cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A detailed analysis of the Phase III ToGA study announced today revealed an unprecedented survival benefit for patients whose tumours exhibited a particularly high level of HER2 when Herceptin (trastuzumab) was added to standard chemotherapy (Xeloda or intravenous 5-FU and cisplatin). (Source: Roche Investor Update)
Source: Roche Investor Update - September 24, 2009 Category: Pharmaceuticals Source Type: organizations

Continuous improvements in animal welfare within Roche ResearchEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche announced the winners of its global 3Rs Award Program - a unique and innovative program that helps to reduce and limit the use of animals in preclinical research - to recognise and reward innovation and continuous improvement in animal welfare within the Roche research organisation. The award, which is now in its second year, is based on the 3Rs concept, which means Replacing animal tests where possible, Reducing the number of animals required and Refining existing scientific practices as well as animal care and husbandry. Fifteen teams of Roche scientists and animal care specialists from the companies’ global ...
Source: Roche Investor Update - September 24, 2009 Category: Pharmaceuticals Source Type: organizations

Anti-Cancer Agent Xeloda and Avastin Obtained Approval for Additional Indication of Colorectal CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Please find enclosed a press release by Chugai (Source: Roche Investor Update)
Source: Roche Investor Update - September 24, 2009 Category: Pharmaceuticals Source Type: organizations

Adding Xeloda to standard chemotherapy before surgery helps to eradicate tumours in patients with early breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Results from the ABCSG 24 trial presented today at the joint 15th ECCO and 34th ESMO 2009 congress, Berlin, Germany showed that the addition of Xeloda (capecitabine) to anthracycline- and taxane-containing regimens prior to surgery (neoadjuvant therapy) led to complete eradication of the tumour in 24% of women with HER2-positive or HER2-negative early breast cancer. The increased efficacy seen obtained by adding Xeloda was measured by an increase in the pathological complete response (pCR) rate from 16% to 24% (hazard ratio of 0.58, p=0.02). This is an important finding since the proportion of women whose tumour completely...
Source: Roche Investor Update - September 23, 2009 Category: Pharmaceuticals Source Type: organizations

From inoperable disease to potentially life saving surgery - new Avastin data gives hope to colorectal cancer patients with liver metastasesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
New data from several studies presented at ECCO 151 and ESMO 342 confirm unique benefits of Avastin (bevacizumab) and Xeloda (capecitabine) in treatment of colon cancer (Source: Roche Investor Update)
Source: Roche Investor Update - September 23, 2009 Category: Pharmaceuticals Source Type: organizations

Roche announces results from two early studies which show promise for patients with malignant melanomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
New data from phase II Avastin study and a phase I extension study of highly selective BRAF inhibitor (Source: Roche Investor Update)
Source: Roche Investor Update - September 23, 2009 Category: Pharmaceuticals Source Type: organizations

Phase IV lung cancer study confirms the safety and outstanding efficacy benefit of Avastin-based therapy in a 'real world' setting.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Key data from four presentations at the joint ECCO 15 and ESMO 34 congress strongly support the clinical benefit of Avastin in advanced non-small cell lung cancer (NSCLC) (Source: Roche Investor Update)
Source: Roche Investor Update - September 23, 2009 Category: Pharmaceuticals Source Type: organizations

Reminder: Roche Investor Science Event: Conference Call from ECCO ESMO 2009 - Friday, September 25th, 2009Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We are pleased to invite you to a Conference Call to discuss new data on Roche’s oncology products and pipeline being presented during the joint 15th Congress of the European Cancer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO), which runs from September 20th – September 24th, 2009 in Berlin, Germany. (Source: Roche Investor Update)
Source: Roche Investor Update - September 21, 2009 Category: Pharmaceuticals Source Type: organizations

Roche to present new survival data from phase II, III and IV studies for Avastin, Herceptin and XelodaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nearly 150 abstracts covering new tumour types, new patient groups and existing indications to feature in ECCO-ESMO program Roche will present encouraging results from nearly 150 scientific studies investigating use of its major cancer medicines at ECCO 15 ESMO 34, which opens in Berlin, Germany today. Overall survival benefits will be demonstrated for Avastin (bevacizumab) in malignant melanoma and for Herceptin (trastuzumab) in gastric cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - September 21, 2009 Category: Pharmaceuticals Source Type: organizations

Antineoplastic Agent / Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, TarcevaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Application for Approval of Additional Indication of Pancreatic Cancer (Source: Roche Investor Update)
Source: Roche Investor Update - September 18, 2009 Category: Pharmaceuticals Source Type: organizations

Study shows MabThera maintenance treatment delays disease progression in patients with incurable lymphomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Results show patients treated with MabThera as initial and follow-on therapy stay in remission for longer. Roche announced today results from the international phase III study PRIMA1, which show that MabThera (rituximab) maintenance therapy can significantly increase the time until the disease progresses in newly-treated patients with advanced follicular lymphoma, a common and slow-developing but incurable form of lymphoma. (Source: Roche Investor Update)
Source: Roche Investor Update - September 17, 2009 Category: Pharmaceuticals Source Type: organizations

Roche's Third Quarter Sales 2009 Conference CallEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche will publish its Sales Results for the 3rd Quarter of 2009 prior to the opening of the Swiss Stock Exchange on Thursday 15th October, 2009. (Source: Roche Investor Update)
Source: Roche Investor Update - September 14, 2009 Category: Pharmaceuticals Source Type: organizations

Roche Investor Science Event: Conference Call from ECCO ESMO 2009 - Friday, September 25th, 2009Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We are pleased to invite you to a Conference Call to discuss new data on Roche’s oncology products and pipeline being presented during the joint 15th Congress of the European Cancer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO), which runs from September 20th – September 24th, 2009 in Berlin, Germany. (Source: Roche Investor Update)
Source: Roche Investor Update - September 11, 2009 Category: Pharmaceuticals Source Type: organizations

Roche announces new Corporate Executive CommitteeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
William M. Burns, Juergen Schwiezer and Jonathan Knowles to retire – Pascal Soriot appointed COO Pharma Division and Daniel O’Day appointed COO Diagnostics Division – Jean-Jacques Garaud and Dan Zabrowski to become Members of Enlarged Executive Committee – Ian Clark appointed CEO Genentech (Source: Roche Investor Update)
Source: Roche Investor Update - September 8, 2009 Category: Pharmaceuticals Source Type: organizations

Roche recognised as new Super Sector Leader in Dow Jones Sustainability IndexEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche (SIX: RO, ROG; OTCQX: RHHBY) has been rated as the new Super Sector Leader in Healthcare on the Dow Jones Sustainability Index, placing Roche as the most sustainable healthcare company worldwide. Selection into the global Dow Jones Sustainability World Index as well as the pan-European Dow Jones STOXX Sustainability Index follows a thorough analysis of corporate economic, environmental and social performance, and takes into account elements such as corporate governance, risk management, access to medicines, climate change, supply chain standards, stakeholder engagement and labor practice. (Source: Roche Investor Update)
Source: Roche Investor Update - September 3, 2009 Category: Pharmaceuticals Source Type: organizations

Roche receives CE Mark certification for cobas 8000 modular analyzer seriesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche announced today that the CE Mark certification for cobas 8000 modular analyzer series has been granted allowing commercial distribution of the first analyzers in Europe as well as in all countries recognizing the CE Mark in the EMEA, Latin America and Asia-Pacific regions. (Source: Roche Investor Update)
Source: Roche Investor Update - September 1, 2009 Category: Pharmaceuticals Source Type: organizations

FDA Approves Valcyte (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney TransplantsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Plus new oral solution offers dosing flexibility for pediatric patients. Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Valcyte (valganciclovir hydrochloride) for the prevention of cytomegalovirus (CMV) disease in pediatric kidney and heart transplant patients (4 months to 16 years of age) at high risk of developing CMV disease. The FDA also approved a new pediatric oral solution formulation for Valcyte, which will allow easier administration to pediatric patients 4 months to 16 years of age. (Source: Roche Investor Update)
Source: Roche Investor Update - August 31, 2009 Category: Pharmaceuticals Source Type: organizations

Roche and Lonza Announce Opt-in for Singapore Manufacturing FacilityEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche and Lonza announced today that Genentech Singapore Pte. Ltd. (“Genentech Singapore”), a wholly-owned member of the Roche Group, elected to exercise an option to purchase from Lonza its cell culture biologic manufacturing facility in Singapore. The facility, which is mechanically complete, will be merged with Genentech Singapore's existing biologic manufacturing facility. (Source: Roche Investor Update)
Source: Roche Investor Update - August 31, 2009 Category: Pharmaceuticals Source Type: organizations

Avastin plus commonly used chemotherapies improves time without the disease getting worse in women with previously treated advanced breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a Phase III study of Avastin (bevacizumab) in combination with a range of chemotherapies met its primary endpoint of increasing the time women with previously treated advanced HER2 negative breast cancer lived without the disease getting worse (progression-free survival or PFS) compared to chemotherapy alone. In the RIBBON-2 study, investigators chose the type of chemotherapy used in combination with Avastin and the chemotherapies were assessed together in the primary endpoint analysis. (Source: Roche Investor Update)
Source: Roche Investor Update - August 18, 2009 Category: Pharmaceuticals Source Type: organizations

Roche Continents takes place for the third timeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
For the third time, Roche and the Salzburg Festival have invited 100 students to take part in "Roche Continents". Students of science, music and the fine arts from 21 European countries will be spending a week together in Salzburg discussing the topic of creativity in their fields of study and uncovering the common ground in what at first glance seem to be very different disciplines. (Source: Roche Investor Update)
Source: Roche Investor Update - August 5, 2009 Category: Pharmaceuticals Source Type: organizations

Avastin approved in US for the most common type of kidney cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin (bevacizumab) plus interferon alpha for people with metastatic renal cell carcinoma, the most common type of kidney cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - August 3, 2009 Category: Pharmaceuticals Source Type: organizations

Phase III study showed Tarceva helped patients with advanced non-small cell lung cancer live longer when used immediately after initial chemotherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche today announced that patients with advanced non-small cell lung cancer (NSCLC) who received Tarceva (erlotinib) immediately after initial chemotherapy in SATURN, a pivotal Phase III study, had a significant, 23% improvement in overall survival (hazard ratio =0.81; p-value=0.0088) compared to patients who received placebo. As previously announced, the safety results in this study were consistent with what has been seen before and there were no new or unexpected safety signals. Overall survival was a key secondary endpoint of the study and these new survival data were presented during the ongoing 13th World Conference ...
Source: Roche Investor Update - August 1, 2009 Category: Pharmaceuticals Source Type: organizations

FDA accepts complete response resubmission for ACTEMRA (tocilizumab)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche announced today that the U.S. Food & Drug Administration (FDA) has accepted the resubmission for the ACTEMRA (tocilizumab) Biologics License Application (BLA), following the company’s receipt of a complete response in September 2008. The FDA has designated a Class II, or six-month, review timeline for the resubmission, according to Prescription Drug User Fee Act (PDUFA) guidelines. ACTEMRA is the first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). (Source: Roche Investor Update)
Source: Roche Investor Update - July 31, 2009 Category: Pharmaceuticals Source Type: organizations

Second Phase III Study Showed Lucentis Improved Vision in Patients with Retinal Vein OcclusionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche announced today that the Phase III study CRUISE showed Lucentis (ranibizumab injection) improved vision in patients with swelling in the retina (macular edema) due to central retinal vein occlusion (RVO). (Source: Roche Investor Update)
Source: Roche Investor Update - July 30, 2009 Category: Pharmaceuticals Source Type: organizations

European commission approves broader label for Avastin allowing combination with docetaxel for the first-line treatment of advanced (metastatic) breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
More patients with advanced breast cancer could benefit from Avastin as a result of a broader label allowing Avastin to be combined with both docetaxel or paclitaxel chemotherapy, Roche announced today. In March 2007, Avastin was approved in Europe for the first-line treatment of patients with advanced breast cancer, in combination with paclitaxel. (Source: Roche Investor Update)
Source: Roche Investor Update - July 29, 2009 Category: Pharmaceuticals Source Type: organizations

Genentech Announces Appointment of Sandra J. Horning, M.D., to Senior Vice President, Global Head, Clinical Development Hematology/OncologyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the appointment of Sandra J. Horning, M.D., to senior vice president, global head, Clinical Development Hematology/Oncology. (Source: Roche Investor Update)
Source: Roche Investor Update - July 28, 2009 Category: Pharmaceuticals Source Type: organizations

Roche and Google.org Start Initiative for Early Discovery of New DiseasesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche Applied Science and Google.org recently started a joint project to demonstrate the feasibility of developing a multidisciplinary surveillance, research and response system. This system will enhance the ability to predict and prevent emerging infectious diseases in East Africa. Roche has donated a Genome Sequencer FLX system as backbone of this project.“We are proud to work with Google.org, and the dedicated research organizations in Kenya to bring this technology to a region of the world where novel viruses frequently emerge. We are confident that access to the 454 Sequencing Systems will improve monitoring of ...
Source: Roche Investor Update - July 28, 2009 Category: Pharmaceuticals Source Type: organizations

MabThera receives positive opinion in Europe for treating patients whose chronic lymphocytic leukaemia returnsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Roche announced today that the European Union’s Committee on Human Medicinal Products (CHMP) has issued a positive recommendation for the use of MabThera (rituximab) in patients with relapsed or refractory chronic lymphocytic leukaemia (CLL). Physicians will soon be able to prescribe MabThera, the first monoclonal antibody therapy approved for previously untreated CLL, in combination with chemotherapy to patients who have been treated for the disease but whose cancer has returned or have not appropriately responded to therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - July 24, 2009 Category: Pharmaceuticals Source Type: organizations

Full reconciliation of Chugai interim results into IFRSEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Following the publication of Chugai’s official 2009 interim results, Roche offers this investor update which reconciles these results with the results for Chugai published by Roche as part of the Roche Group’s 2009 interim results. (Source: Roche Investor Update)
Source: Roche Investor Update - July 24, 2009 Category: Pharmaceuticals Source Type: organizations

Double-digit increase in sales, operating profit and Core EPSEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Integration of Genentech progressing rapidly; full-year outlook raised; Group sales up 2 billion to 24 billion Swiss francs, an increase of 10% in local currencies (9% in Swiss francs); both divisions grow significantly faster than their respective markets. (Source: Roche Investor Update)
Source: Roche Investor Update - July 23, 2009 Category: Pharmaceuticals Source Type: organizations